DNLI Q3 2018 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

$1M100.0% margin

Operating Income

-$38M-3176.9% margin

Net Income

-$35M-2959.9% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

-27.5%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$36M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$544M

Total Liabilities

$83M

Stockholders' Equity

$461M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	$1M	$0	—
Operating Income	-$38M	-$22M	-70.3%
Net Income	-$35M	-$22M	-61.9%